Forecast Bio discloses $2.4M SAFE financing for its astrocyte AI platform

Forecast Bio's filing covers nine investors, with the first sale dating to November 2025 and $750,000 of the offering still open.

By · Published

Primary source: U.S. Securities and Exchange Commission

Why it matters

Forecast is testing whether astrocyte activity can become a predictive measurement for psychiatric drug development, giving developers another way to assess candidates before clinical trials.

A vast paper-cut 3D render of an interconnected astrocyte AI platform with abstract financial document shapes and a tiny human figure.

Forecast Bio, founded by UCSF neuroscientist Kira Poskanzer, has disclosed $2.4 million in SAFE financing for an AI platform intended to predict how psychiatric drugs affect human brain circuits and symptoms.…

Reader comments

Conversation for this story loads after sign-in.